MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
तुलना करने के लिए मीट्रिक्स | MGNX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधMGNXपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −2.9x | −2.4x | −0.4x | |
PEG अनुपात | 0.29 | 0.26 | 0.00 | |
क़ीमत/बुक | 3.9x | 2.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 1.5x | 7.4x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 11.1% | 43.6% | 51.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 0.7% | 6.8% | अनलॉक करें |